Physician profile
Marian E Deames
NPI 1891100863
$1,802.24
in general payments reported to CMS, 2019-2025
27 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $83.85 · 2021: $323 · 2022: $57.20 · 2023: $262 · 2024: $339 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.42 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $260.99 | 2021-2025 | Airsupra, Breztri, Seroquel |
| Abbvie INC. | $178.02 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $165.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $149.97 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $121.72 | 2019-2025 | Rexulti |
| Pfizer INC. | $112.12 | 2020-2025 | |
| Amarin Pharma, INC. | $51.45 | 2021 | |
| Exact Sciences Corporation | $45.22 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $40.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.07 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $37.54 | 2025 | Gemtesa |
| Amgen INC. | $32.38 | 2019-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.51 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $27.78 | 2025 | Rexulti |
| Astellas Pharma US INC | $26.39 | 2025 | Veozah |
| Sage Therapeutics, LLC | $22.69 | 2025 | Zurzuvae |
| Abbott Laboratories | $20.05 | 2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $18.88 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2021 | |
| Eisai INC. | $17.18 | 2019 | |
| Dexcom, INC. | $16.22 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $16.21 | 2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $16.20 | 2025 | Nexletol |
| Phadia US INC. | $15.32 | 2020 | |
| Allergan, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Deames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.